Related references
Note: Only part of the references are listed.Osteopontin-integrin αvβ3 axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma
Takuya Nakamura et al.
FEBS LETTERS (2015)
Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer
Maria Thadani-Mulero et al.
CANCER RESEARCH (2014)
Nanoways to overcome docetaxel resistance in prostate cancer
Aditya Ganju et al.
DRUG RESISTANCE UPDATES (2014)
Epithelial-to-Mesenchymal Transition Mediates Docetaxel Resistance and High Risk of Relapse in Prostate Cancer
Mercedes Marin-Aguilera et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Hallmarks of alternative splicing in cancer
S. Oltean et al.
ONCOGENE (2014)
Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors
Kai-Hsi Hsu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2014)
Human osteopontin splicing isoforms: Known roles, potential clinical applications and activated signaling pathways
E. R. Gimba et al.
CANCER LETTERS (2013)
Promising New Molecular Targeted Therapies in Head and Neck Cancer
Kelly Dorsey et al.
DRUGS (2013)
Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
Michel D. Wissing et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance
L. Chang et al.
CELL DEATH & DISEASE (2013)
The changing landscape in metastatic castration-resistant prostate cancer
Raya Leibowitz-Amit et al.
CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2013)
Upregulation of Drug Transporter Expression by Osteopontin in Prostate Cancer Cells
I-Shan Hsieh et al.
MOLECULAR PHARMACOLOGY (2013)
Epithelial-to-Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and Is Mediated by Reduced Expression of miR-200c and miR-205
Martin Puhr et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells
Tatiana M. Tilli et al.
PROSTATE (2012)
Pre- and post-translational regulation of osteopontin in cancer
Pieter H. Anborgh et al.
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2011)
Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines
Modjtaba Emadi Baygi et al.
CELL BIOLOGY AND TOXICOLOGY (2010)
Osteopontin: An Effector and an Effect of Tumor Metastasis
L. A. Shevde et al.
CURRENT MOLECULAR MEDICINE (2010)
N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer
Karin Jennbacken et al.
ENDOCRINE-RELATED CANCER (2010)
Therapy-Induced Senescence in Cancer
Jonathan A. Ewald et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity
Justin D. Blasberg et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2010)
The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways
Donald Courter et al.
PLOS ONE (2010)
Effects of Oxidative Stress on Mouse Embryonic Stem Cell Proliferation, Apoptosis, Senescence, and Self-Renewal
Yan-Lin Guo et al.
STEM CELLS AND DEVELOPMENT (2010)
Tumorigenic properties of alternative osteopontin isoforms in mesothelioma
Sergey V. Ivanov et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Expression of Multidrug Resistance Proteins in Prostate Cancer Is Related With Cell Sensitivity to Chemotherapeutic Drugs
Catherine Sanchez et al.
PROSTATE (2009)
A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
Kim N. Chi et al.
CLINICAL CANCER RESEARCH (2008)
Osteopontin as a target for cancer therapy
Nicholas I. F. Johnston et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Osteopontin-c is a selective marker of breast cancer
Mana Mirza et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3
M. Graessmann et al.
ONCOGENE (2007)
Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy
Subbareddy Maddika et al.
DRUG RESISTANCE UPDATES (2007)
Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells
S. G. Patterson et al.
ONCOGENE (2006)
Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity
Josep Domingo-Domenech et al.
CLINICAL CANCER RESEARCH (2006)
An osteopontin splice variant induces anchorage independence in human breast cancer cells
B He et al.
ONCOGENE (2006)
Osteopontin: role in cell signaling and cancer progression
H Rangaswami et al.
TRENDS IN CELL BIOLOGY (2006)
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer
AW Tolcher et al.
CLINICAL CANCER RESEARCH (2005)
Multiple Roles of the PI3K/PKB (Akt) Pathway in Cell Cycle Progression
Jiyong Liang et al.
CELL CYCLE (2003)
P700: the primary electron donor of photosystem I
AN Webber et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS (2001)